Slide 1: Investors deck
PolyPid Investors deck August 2026
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation of PolyPid Ltd. (the “Company”) contains “forward- However, there can be no assurance that management’s looking statements” within the meaning of the Private Securities expectations, beliefs and projections will be achieved and actual Litigation Reform Act
Slide 3: Company Snapshot
Company Snapshot PolyPid is an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins. Core Technology Lead Product Kynatrix Long-Acting, D-PLEX100 target PDUFA date of Controlled-Release Technology November 28, 2026
Slide 4: The Power of Uncompromising Precision
The Power of Uncompromising Precision Substance Versatility Zero-Burst Release Customizable Duration Suitable for antibiotics, cytotoxic agents, No initial drug spike Tunable from several days peptides, nucleic acids, and more. to several weeks. Layered Matrix Architecture Scalable Manufacturing Pro
Slide 5: Introducing the Kynatrix Technology
Introducing the Kynatrix” Technology
Slide 6: Introducing The Kynatrix Technology
Introducing The Kynatrix Technology Drug molecules are embedded Body moisture activates the platform, Release is sustained and customizable within the alternating polymer- triggering controlled surface for days to weeks lipid layers degradation of the polymer-lipid matrix and constant, linear drug r
Slide 7: Portfolio Flagship Product: D-PLEX100
Portfolio Flagship Product: D-PLEX100 What is it? A high-concentration doxycycline formulation (broad-spectrum antibiotic) delivered locally over 30 days. Indication for Use Prevention of surgical site infections (SSIs) following abdominal colorectal surgery. Prevalence: 15%–25% SSI in abdominal sur
Slide 8: Easily Applied in Any Surgical Setting
Easily Applied in Any Surgical Setting Instruction for use: D-PLEX100 applied in abdominal surgery: 8
Slide 9: The Largest Phase III Trial for Prevention of SSI in Over a Decade
The Largest Phase III Trial for Prevention of SSI in Over a Decade Population Patients undergoing elective abdominal colorectal surgery with incision length > 20 cm Primary efficacy endpoint Reduction in SSI, mortality and reintervention within 30 days post index surgery Trial size Global trial US,
Slide 10: Phenomenal Phase III Clinical Trial Results
Phenomenal Phase lll Clinical Trial Results Primary Efficacy Endpoint Surgical Site Infection (SSI) ASEPSIS Score >20 (ITT cohort) (ITT Cohort) (ITT Cohort) 71 (18.1%) 40% RRR (p=0.0039) 36 21 60% 64% 43 (9.5%) RRR (5.6%) RRR (10.9%) (p=0.0013) (p=0.0103) 15 8 (3.8%) (2.0%) SoC* D-PLEX100 + SOC SoC*
Slide 11: A Potential Multi-Million-Dollar Opportunity
A Potential Multi-Million-Dollar Opportunity 12M/Year US total addressable market in-patient surgical procedures 4.4M/Year Abdominal Surgeries Includes colorectal, gyn, urology, and high-risk procedures 11 **Source IQVIA PM&I Global FlexView. Internal analysis
Slide 12: Azurity Partnership Valued at >$320M
Azurity Partnership Valued at >$320M U.S. and Canada Commercial Partnership FINANCIAL TERMS DEAL STRUCTURE Upfront Payment: Scope $30M in upfront and near-term milestone U.S. and Canada. PolyPid retains rights for all payments: $15M at signing and $15M upon FDA other territories acceptance (expected
Slide 13: Demonstrated Economic Incentive to Drive Adoption
Demonstrated Economic Incentive to Drive Adoption Direct cost SSI costs ~$30K/patient1 on average • Prolonged length of stay and higher readmission rates • Re-operation in some cases (to debride and remove infected / necrotic tissues) Indirect cost CMS 1-3% penalty on all the yearly Hospital Medicar
Slide 14: Surgeons perceive D-PLEX100 to be more valuable than current interventions
Surgeons perceive D-PLEX100 to be more valuable overall than currently used interventions How likely are you to prescribe D-PLEX100 to prevent Most Mentioned Patients Appropriate for D-PLEX100 SSIs in eligible surgical patients? (% of responders) Patient with a higher risk of infection immunocomprom
Slide 15: Pharmacy Directors expect high likelihood of formulary coverage and stocking
Pharmacy Directors expect high likelihood of formulary coverage and stocking of D-PLEX100 Value perception and likelihood for formulary coverage and stocking are high and grow even higher with the introduction of NTAP Likelihood of formulary converge and stocking of D-PLEX100 (% of responders) Extre
Slide 16: Manufacturing Excellence Enabling Global Scale
Manufacturing Excellence Enabling Global Scale PolyPid operates an 18,000 sq. ft., state-of-the-art GMP facility purpose-built for its .proprietary Kynatrix drug-delivery technology The site enables precise, reproducible production of our proprietary formulations and supports scalable manufacturing
Slide 17: Always Delivering, Our Milestones Too
Always Delivering, Our Milestones Too Expected Timeline ✓ ↓ ↓ ↓ ↓ ↓ July 2026 Q3 2026 Oct. 2026 Nov. 28, 2026 Early 2027 H2 2027 NDA Submission - EU Submission Submission for NTAP PDUFA Target Expected launch EU approval Accepted reimbursement date ✓ Completed ✓ Completed ✓ NDA Submission Completed
Slide 18: Innovation Strategy
Innovation Strategy Our strategy is to leverage the power of our Kynatrix delivery technology to elevate treatment effectiveness Collaborate with R&D partners to: Eliminate systemic side Improve efficacy Extend molecule ½ life effects and toxicity Key Therapeutic Areas Surgical Site Infection Metabo
Slide 19: Innovation Pipeline
Therapeutic Area ssi Metabolic Disease Oncology 19 Innovation Pipeline Current Pipeline Product name Pre-Clinical Phase 1 Phase 2 Phase 3 Regulatory Review Indicated for prevention of surgical site infections (SSIs) following abdominal colorectal surgery. PDUFA target date November 28, 2026. Ultra-l
Slide 20: Financials
Financials Stock Information Analyst coverage Listing NASDAQ Ticker PYPD 52-week range1 $3.06-$5.73 Market cap1 $110 M Share Structure2 Shares outstanding 20.3 M Shares held in 2.8 M abeyance Warrants 0.5 M @ $3.61 exercise price (Expired Aug. 6, 2026) Warrants 7.3 M @ $4.50 exercise price Options o
Slide 21: Built for Scale and Growth
Built for Scale and Growth Large, Attractive Market Opportunity Addressing a substantial global market of 12M surgeries annually with significant unmet need in surgical site infection prevention. Multiple Near-Term Catalysts Expected PDUFA date November 28, 2026 Innovation-Driven Pipeline A growing
Slide 22: Thank You!
Thank You! Polyrid